Skip to main content
13/03/2024

A family from Malaga donates €15,080 for research against Childhood Sarcoma at VHIR

Sin Piedad donacio

13/03/2024

The 'Sin Piedad' initiative tells the story of David, a boy who is undergoing treatment for paediatric cancer, an example of a resilient attitude in the face of illness

The "Sin Piedad contra el Cáncer" initiative has donated €15,080 to the Sarcoma Laboratory of the Childhood Cancer and Blood Diseases group at the Vall d'Hebron Research Institute (VHIR). "Sin Piedad!", is a battle cry that ended up becoming a ritual and a combative spirit for a family from Malaga when their son was diagnosed with paediatric cancer. A symbol represented by a fist and materialised in T-shirts that have become the "uniform" with which David and his family always go to the hospital, joining their fists together to the united cry of "Sin Piedad!" They shared their story through their Instagram account: @sinpiedadcontraelcancer and sparked the solidarity and empathy of thousands of people who wanted to join David's fight by buying T-shirts and sending videos to the Instagram account, joining in the cry of "Sin Piedad contra el cáncer". Thus, virtually spontaneously, an initiative was born that has raised funds for the fight against cancer.

The €15,080 will go to the project "Development of new therapies for childhood sarcomas". Sarcomas are a very diverse type of malignant connective tissue tumour formed by the proliferation of mesoderm cells that can originate in a wide variety of tissues. VHIR is studying several specific molecular targets present in these cancers. All of them are essential proteins for tumour development, whose pharmacological blockade can lead to the paralysis of tumour growth. Dr. Josep Roma, head of the Sarcoma Laboratory at VHIR, explains that "the ultimate goal of the project is to increase the pharmacological arsenal available to fight this disease, especially in cases that do not respond to conventional therapy".   

Related news

A study, co-led by Vall d’Hebron, has analysed the evolution of clinical trials with children and adolescents with cancer over the last 15 years, with the aim of optimising efficacy and defining lines for further progress.

The research team has shown that inhibiting the TRIB3 protein slows the growth of rhabdomyosarcoma and improves survival in animal models.

Vall d'Hebron presents positive results from two studies in transfusion-dependent thalassaemia and severe bone marrow aplasia at the EBMT Annual Meeting on haematopoietic stem cell transplantation.

Related professionals

Josep Roma  Castanyer

Josep Roma Castanyer

Main researcher
Childhood Cancer and Blood Disorders
Read more
Maria Isabel  Benitez  Carabante

Maria Isabel Benitez Carabante

Childhood Cancer and Blood Disorders
Read more
Raquel Hladun Alvaro

Raquel Hladun Alvaro

Predoctoral researcher
Childhood Cancer and Blood Disorders
Read more
Maria Eugenia Bustelo Almeida

Maria Eugenia Bustelo Almeida

Research technician
Childhood Cancer and Blood Disorders
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.